Target intelligence / Profile preview

Butyrophilin subfamily 3 member A3 (BTN3A3)

Target
BTN3A3
Molecular classification
Receptor, Immunoglobulin superfamily, Butyrophilin family
01

Overview

Butyrophilin subfamily 3 member A3 (BTN3A3) is a type I membrane glycoprotein of the immunoglobulin superfamily encoded on human chromosome 6 within the MHC-associated butyrophilin gene cluster. Its ectodomain forms V-shaped homodimers and is structurally homologous to the B7 superfamily; BTN3A-specific antibodies bind distinct epitopes on the IgV domain and can either stimulate or inhibit Vγ9Vδ2 T-cell responses, indicating a role for BTN3A molecules in modulating γδ T-cell activation in infection and cancer contexts. UniProt and InterPro annotate BTN3A3 as playing a role in T-cell responses in adaptive immunity. Wikipedia and NCBI confirm BTN3A3 as the human protein/gene name and locus information.

Other names
CD277BTN3.1/BTN3A3
02

Mechanism of action

Agonist anti-BTN3A antibodies can mimic phosphoantigen-mediated activation of Vγ9Vδ2 T cells by binding BTN3A IgV domain epitopes, modulating T-cell activation signaling. Antagonist anti-BTN3A antibodies can inhibit Vγ9Vδ2 T-cell reactivity by binding distinct BTN3A epitopes and blocking activation.

03

Biological functions

Immune responseSignal transduction
04

Disease associations

CancerInfectionOther
05

Safety considerations

On-target immune modulation risks (overactivation or suppression of T-cell responses) when targeting BTN3A family with agonist/antagonist antibodies; extrapolated from its role in T-cell activation pathways
06

Interacting drugs

Agonist and antagonist antibodies to BTN3A
07

Biomarkers

BTN3A3 expression on tumor or immune cells as a potential biomarker to stratify responses to anti-BTN3A modulators within the BTN3A family context

Beyond the preview

Go deeper on Butyrophilin subfamily 3 member A3 (BTN3A3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Butyrophilin subfamily 3 member A3 (BTN3A3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call